Consistent, high-volume, low-cost Colombian cannabis company selling into multiple global markets

With low-cost production and international exports, this Colombian cannabis company is seeking a $3M partner. Backed by $15M in contracts, it offers year-round premium strains and is targeting EU-GMP certification by 2026. Proven scalability and high-margin potential make this an attractive global opportunity.

• Well-established and well-positioned Colombian medical cannabis company poised to become a leading and reliable global wholesale cannabis supplier with consistent supply year-round.

• Export track record: >10 successful international shipments; one of a small number of Colombian licensees consistently exporting to regulated markets

• Attractive high growth business model with recurrent & predictable revenues and high margin potential (60%+ EBITDA margin at scale)

• Low-cost, high-margin model driven by Colombian production advantages between $0.10-$0.30 cost per gram vs. $0.80 – 1.50 per gram in EU / North America.

• Proven scale with past rolling harvests of up to 1,000 kgs per month. Demonstrating ability to scale to meet market demand

• $15M+ in multi-year, recurring revenue contracts secured across Australia, Germany, the UK, Italy, Malta and Poland

• Company has 30 high quality, registered strains in their genetics library, all developed in Colombia, with one of Colombia’s leading genetics teams under the leadership of their Canadian cultivation and genetics experts

• Company also has a number of unique strains that are testing at 24-27% THC in the pipeline and more underway. Adding to genetics library and fine tuning the production approach for maximum cannabinoid and terpene plant expression.

• Highly experienced management team and leadership governance, with strong expertise in cultivation, pharma and distribution. Board includes former regional President of Philip Morris International and Director of Imperial Brands ($30bn market cap).

• Consistent quality meeting EU Pharmacopeia and TG93 standards; recently achieved CUMCS-GACP certification

• Upgraded infrastructure to meet EU-GACP standards and initiated EU-GMP roadmap for 2026 to enhance quality, streamline supply chains, and boost margins

• One greenhouse currently operational, with a second set to launch in Q3 2025. The site has capacity for 8 more greenhouses, offering full monetization of licensed land and ~$1–$4M+ in annual revenue potential per greenhouse